Skip to Content
Last Updated: 10/05/2016

DCTD Announces Precision Medicine Initiative Administrative Supplement Grantees

In 2016, President Obama announced a Precision Medicine Initiative® (PMI) to advance health and treatments for disease through research that considers an individual’s genes, lifestyle, and environment. The PMI provided FY2016 resources to FDA and NIH, including funding for NCI to focus research in precision medicine in oncology. Discussions and collaborations among staff across NCI’s divisions led to the development of NCI’s PMI oncology strategic areas. As part of NCI’s contribution to this initiative, DCTD directed new funding towards expanding its portfolio of genomic-based clinical trials, improving our understanding of resistance to targeted agents and drug combinations, and developing a mechanistic understanding of immunotherapy. The PMI was also focused on improving pre-clinical models for evaluating targeted therapeutics. Finally, a major component of this overall effort was the 2016 launch of NCI’s Genomic Data Commons (GDC), which is a data sharing platform for precision medicine in oncology. Molecular data from DCTD-supported clinical trials will be deposited into the GDC in order to foster and encourage data mining and secondary analyses by a broad range of investigators.

To begin this initiative, and to accelerate progress in multiple areas, DCTD announced a series of administrative 1-year supplement awards for 2016. Eligible parent grants for these supplements included P30 (Cancer Centers), P50 (SPORES), and UM1 / U10 Cooperative Agreements (Experimental Therapeutics Clinical Trials Network - ETCTN and National Clinical Trials Network - NCTN, respectively). In total, 53 awards were made for this supplement initiative from a total of 144 applications. In the coming years, DCTD hopes to spark increased activity in the areas that were supplemented in 2016 by issuing Requests for Applications (RFAs) on these topics.

The six scientific areas that were supplemented in September 2016 and the projects’ Principal Investigators (PIs) are listed below:

Improvements and Optimization of T-cell Therapies and cGMP Manufacturing Processes for Production of Autologous T-cell Therapy Products Targeting Solid Cancers

Project PI(s) Parent Grant PI Institution
Chantale Bernatchez,
Elizabeth Shpall
Ronald DePinho University of Texas, MD Anderson Cancer Center
Linda Kelley,
James Mulé
Thomas A. Sellers H. Lee Moffitt Cancer Center and Research Institute
Isabelle Rivière,
Michel Sadelain
Craig B. Thompson Sloan-Kettering Institute for Cancer Research

Biomarker Studies Associated with NCI-supported Clinical Trials of Immunotherapy

Project PI(s) Parent Grant PI Institution
Michael B. Atkins,
Geoffrey T. Gibney
Louis M. Weiner Georgetown University
Lisa H. Butterfield Nancy E. Davidson University of Pittsburgh
Martin (Mac) Cheever Gary D. Gilliland Fred Hutchinson Cancer Research Center
Sandra P. D’Angelo Monica M. Bertagnolli Brigham and Women’s Hospital, Alliance for Clinical Trials in Oncology
Thomas Gajewski Michelle M. Le Beau University of Chicago
David Gerber Melanie H. Cobb University of Texas, Southwestern Medical Center
F. Stephen Hodi Edward J. Benz Dana-Farber Cancer Institute
Michael Lim Stuart A. Grossman Adult Brain Tumor Consortium
Patricia M. LoRusso Peter G. Schulam Yale University
Emanuel Maverakis,
Joseph Tuscano
Ralph W. de Vere White University of California, Davis
Kunle Odunsi Kunle Odunsi Roswell Park Cancer Institute
Ravi Salgia Steven T. Rosen Beckman Research Institute/City of Hope
Ignacio I. Wistuba Ronald A. DePinho University of Texas, MD Anderson Cancer Center

Mechanisms of Cancer Sensitivity and Resistance to Therapy Utilizing Samples and Information from Human Clinical Trials

Project PI(s) Parent Grant PI Institution
Nathalie Agar,
Jann Sarkaria,
Forest White
Tyler Jacks Massachusetts Institute of Technology
Carlos L. Arteaga Carlos L. Arteaga Vanderbilt University Medical Center
Himisha Beltran,
Martin Gleave,
Susan Halabi,
Alexander Wyatt
Monica M. Bertagnolli Brigham and Women’s Hospital, Alliance for Clinical Trials in Oncology
Brian J. Druker Brian J. Druker Oregon Health & Science University
Felix Fang Alan Ashworth University of California, San Francisco
Christos Hatzis,
Lajos Pusztai
Peter G. Schulam Yale University
Ross Levine Craig B. Thompson Sloan-Kettering Institute for Cancer Research
Don Nguyen,
Katerina Politi,
Narendra Wajapeyee   
Roy S. Herbst Yale University, SPORE grant
Katherine Pogue-Geile Norman Wolmark NRG Oncology Foundation, Inc
Thomas Witzig Robert B. Diasio Mayo Clinic Cancer Center

Administrative Supplements for Research in Canine Immunotherapy via Collaboration of NCI-designated Cancer Centers and Veterinary Medical Colleges

Project PI(s) Parent Grant PI Institution
Amy Heimberger Ronald A. DePinho University of Texas, MD Anderson Cancer Center
Katherine Janeway Edward J. Benz Dana-Farber Cancer Institute
Deborah Knapp Timothy L. Ratliff Purdue University
Richard Koya Candace S. Johnson Roswell Park Cancer Institute
Jonathan Levitt,
David Wheeler
C. Kent Osborne Baylor College of Medicine
Arta Monjazeb Ralph W. de Vere White University of California, Davis Comprehensive Cancer Center
Peter Shields Michael A. Caligiuri Ohio State University
Jill Slansky Dan Theodorescu University of Colorado, Denver

Studies of How the Microenvironment of Pancreatic Ductal Adenocarcinoma Affects Immunotherapy

Project PI(s) Parent Grant PI Institution
Vinod Balachandran,
Ronald DeMatteo,
Steven D. Leach,
Taha Merghoub,
John Moral,
Jedd Wolchok
Craig B. Thompson Sloan-Kettering Institute for Cancer Research
John Condeelis I. David Goldman Albert Einstein College of Medicine
Howard Crawford,
Marina Pasca di Magliano
Theodore S. Lawrence University of Michigan
David DeNardo Timothy J. Eberlein Washington University
Emma Furth,
Katherine Nathanson,
Anil Rustgi,
Ben Stanger,
Robert Vonderheide
Chi V. Dang University of Pennsylvania
Richard Hynes Tyler Jacks Massachusetts Institute of Technology
Sunil Hingorani Gary D. Gilliland Fred Hutchinson Cancer Research Center
Michael A. Hollingsworth Michael A. Hollingsworth University of Nebraska Medical Center
Kenneth P. Olive Stephen G. Emerson Columbia University Health Sciences

Collaborative Research Efforts to Enhance Preclinical Drug Development and Preclinical Clinical Trials Utilizing Patient Derived Xenograft (PDX) Models

Project PI(s) Parent Grant PI Institution
Carol Bult Edison Tak-Bun Liu Jackson Laboratory
Eva Corey Peter S. Nelson Fred Hutchinson Cancer Research Center
Bingliang Fang John D. Minna University of Texas, Southwestern Medical Center
Barbara Foster Candace S. Johnson Roswell Park Cancer Institute
Michael Lewis C. Kent Osborne Baylor College of Medicine
Funda Meric-Bernstam Funda Meric-Bernstam MD Anderson Cancer Center
Ann Richmond Jennifer A. Pietenpol Vanderbilt-Ingram Cancer Center
Jann Sarkaria Robert Diasio Mayo Clinic Cancer Center
Alana Welm Mary C. Beckerle University of Utah
Agnieszka Witkiewicz Andrew S. Kraft University of Arizona